2026 Q2 -tulosraportti
Tänään
‧30 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 19.8. | ||
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 19.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenAcuCort Q2: Rising revenue, US push ahead today at 08:28 ∙ News overview (AI) AcuCort reported increased revenue for the second quarter of 2026, driven by commercial deliveries of the company's oral film Zeqmelit. Although net loss increased slightly, the company made significant regulatory progress towards entering the US market. Important milestones included securing an FDA agreement on the company's pediatric investigation plan and obtaining a waiver, which paves the way for a planned US marketing application. Revenue in Q2 2026 rose to SEK 1.16 million from SEK 0.16 million in Q2 2025, while net loss increased to SEK 8.20 million. AcuCort secured an FDA agreement on its pediatric investigation plan and a renewed Small Business Waiver, which are important steps towards the company's planned US drug application in 2026. The company delivered its first Nordic order for Zeqmelit, generating SEK 1.1 million, and partnered with Glenmark Pharmaceuticals for European distribution. AcuCort ended the quarter with cash holdings of SEK 10.37 million. https://www.nordnet.dk/markedet/nyheder/18f2c3e3-9158-4680-88a3-b2d3043300f2
Big words as usual from the CEO. Q3 will end with zero revenue. They have 10 million in cash, and increased costs. Here comes big utvaninc- ·7.8.AcuCort changes date for publication of interim report for the second quarter of 2026 The life science company Acucort postpones the publication of its interim report for January-June 2026 to August 19 from the previously announced August 12. The company states that the change is made to ensure that the report is completed with the necessary quality and undergoes usual review and approval before publication.
- ·27.7.AcuCort has received a renewed exemption from the FDA for small businesses – important step ahead of planned NDA application in 2026 https://www.acucort.se/sv/acucort-beviljas-fornyad-small-business-waiver-av-fda-vigtigt-steg-infor-planerad-nda-ansokan-2026/
- ·17.7.So almost 50 hyped meetings in Portugal ended in nothing? Even though they are "super attractive" and customers are running after AcuCort to sell their product (which has zero sales in Scandinavia) 😅 The cash is running out, so it will be exciting to see what the share issue will be set to
Agree with TerryBJones. We had not been promised a big sale in the Nordics, but instead of proving the case, sales in the Nordics have shown us that Zeqmelit apparently cannot be sold. The point is: They have not proven the case. I'm staying far away. I've made quite good money on this one. It could go both ways, but with what they have shown, the company is not worth as much as it currently stands. There are bright spots, but they are hard to see if one has to pay 0.6 per share - at that price, the risk is too great. Otherwise, I love the idea and it's nice that the company is simple. Unfortunately, it's probably as 3D writes, that the relational aspect plays a huge role in Swedish companies. I have completely cut most Swedish companies from my list of companies I'm watching. I have primarily lost money on Swedish companies, yes, except for this one. But if I stick to Danish companies, I make money on the stock market. So this is one of the next ones I'm cutting completely. It's simply too hard to trust Swedish companies (mostly the small ones). They say anything to get investors to bite.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Tänään
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenAcuCort Q2: Rising revenue, US push ahead today at 08:28 ∙ News overview (AI) AcuCort reported increased revenue for the second quarter of 2026, driven by commercial deliveries of the company's oral film Zeqmelit. Although net loss increased slightly, the company made significant regulatory progress towards entering the US market. Important milestones included securing an FDA agreement on the company's pediatric investigation plan and obtaining a waiver, which paves the way for a planned US marketing application. Revenue in Q2 2026 rose to SEK 1.16 million from SEK 0.16 million in Q2 2025, while net loss increased to SEK 8.20 million. AcuCort secured an FDA agreement on its pediatric investigation plan and a renewed Small Business Waiver, which are important steps towards the company's planned US drug application in 2026. The company delivered its first Nordic order for Zeqmelit, generating SEK 1.1 million, and partnered with Glenmark Pharmaceuticals for European distribution. AcuCort ended the quarter with cash holdings of SEK 10.37 million. https://www.nordnet.dk/markedet/nyheder/18f2c3e3-9158-4680-88a3-b2d3043300f2Big words as usual from the CEO. Q3 will end with zero revenue. They have 10 million in cash, and increased costs. Here comes big utvaninc
- ·7.8.AcuCort changes date for publication of interim report for the second quarter of 2026 The life science company Acucort postpones the publication of its interim report for January-June 2026 to August 19 from the previously announced August 12. The company states that the change is made to ensure that the report is completed with the necessary quality and undergoes usual review and approval before publication.
- ·27.7.AcuCort has received a renewed exemption from the FDA for small businesses – important step ahead of planned NDA application in 2026 https://www.acucort.se/sv/acucort-beviljas-fornyad-small-business-waiver-av-fda-vigtigt-steg-infor-planerad-nda-ansokan-2026/
- ·17.7.So almost 50 hyped meetings in Portugal ended in nothing? Even though they are "super attractive" and customers are running after AcuCort to sell their product (which has zero sales in Scandinavia) 😅 The cash is running out, so it will be exciting to see what the share issue will be set toAgree with TerryBJones. We had not been promised a big sale in the Nordics, but instead of proving the case, sales in the Nordics have shown us that Zeqmelit apparently cannot be sold. The point is: They have not proven the case. I'm staying far away. I've made quite good money on this one. It could go both ways, but with what they have shown, the company is not worth as much as it currently stands. There are bright spots, but they are hard to see if one has to pay 0.6 per share - at that price, the risk is too great. Otherwise, I love the idea and it's nice that the company is simple. Unfortunately, it's probably as 3D writes, that the relational aspect plays a huge role in Swedish companies. I have completely cut most Swedish companies from my list of companies I'm watching. I have primarily lost money on Swedish companies, yes, except for this one. But if I stick to Danish companies, I make money on the stock market. So this is one of the next ones I'm cutting completely. It's simply too hard to trust Swedish companies (mostly the small ones). They say anything to get investors to bite.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 19.8. | ||
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 19.8.2025 |
2026 Q2 -tulosraportti
Tänään
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 19.8. | ||
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 19.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenAcuCort Q2: Rising revenue, US push ahead today at 08:28 ∙ News overview (AI) AcuCort reported increased revenue for the second quarter of 2026, driven by commercial deliveries of the company's oral film Zeqmelit. Although net loss increased slightly, the company made significant regulatory progress towards entering the US market. Important milestones included securing an FDA agreement on the company's pediatric investigation plan and obtaining a waiver, which paves the way for a planned US marketing application. Revenue in Q2 2026 rose to SEK 1.16 million from SEK 0.16 million in Q2 2025, while net loss increased to SEK 8.20 million. AcuCort secured an FDA agreement on its pediatric investigation plan and a renewed Small Business Waiver, which are important steps towards the company's planned US drug application in 2026. The company delivered its first Nordic order for Zeqmelit, generating SEK 1.1 million, and partnered with Glenmark Pharmaceuticals for European distribution. AcuCort ended the quarter with cash holdings of SEK 10.37 million. https://www.nordnet.dk/markedet/nyheder/18f2c3e3-9158-4680-88a3-b2d3043300f2Big words as usual from the CEO. Q3 will end with zero revenue. They have 10 million in cash, and increased costs. Here comes big utvaninc
- ·7.8.AcuCort changes date for publication of interim report for the second quarter of 2026 The life science company Acucort postpones the publication of its interim report for January-June 2026 to August 19 from the previously announced August 12. The company states that the change is made to ensure that the report is completed with the necessary quality and undergoes usual review and approval before publication.
- ·27.7.AcuCort has received a renewed exemption from the FDA for small businesses – important step ahead of planned NDA application in 2026 https://www.acucort.se/sv/acucort-beviljas-fornyad-small-business-waiver-av-fda-vigtigt-steg-infor-planerad-nda-ansokan-2026/
- ·17.7.So almost 50 hyped meetings in Portugal ended in nothing? Even though they are "super attractive" and customers are running after AcuCort to sell their product (which has zero sales in Scandinavia) 😅 The cash is running out, so it will be exciting to see what the share issue will be set toAgree with TerryBJones. We had not been promised a big sale in the Nordics, but instead of proving the case, sales in the Nordics have shown us that Zeqmelit apparently cannot be sold. The point is: They have not proven the case. I'm staying far away. I've made quite good money on this one. It could go both ways, but with what they have shown, the company is not worth as much as it currently stands. There are bright spots, but they are hard to see if one has to pay 0.6 per share - at that price, the risk is too great. Otherwise, I love the idea and it's nice that the company is simple. Unfortunately, it's probably as 3D writes, that the relational aspect plays a huge role in Swedish companies. I have completely cut most Swedish companies from my list of companies I'm watching. I have primarily lost money on Swedish companies, yes, except for this one. But if I stick to Danish companies, I make money on the stock market. So this is one of the next ones I'm cutting completely. It's simply too hard to trust Swedish companies (mostly the small ones). They say anything to get investors to bite.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt